Prefer Dr Reddy's, Sun Pharmaceutical: Hemant Thukral

Hemant Thukral of Aditya Birla Money told CNBC-TV18, "The way pharmaceutical index rollovers are happening in the next series, still there is a huge differentiation within the scrip. We cannot see any rollovers happening on stocks like Lupin, for that matter even a Cipla, but rollovers have started picking up in Dr Reddy’s Laboratories and Sun Pharmaceutical."

"In Aurobindo Pharma, the rollovers are still at par or at average, so I would wait for one day more. However, definitely some buying has come back in Dr Reddy's and Sun Pharmaceutical. I feel that Sun Pharmaceutical even in July series can do better from hereon and we are expecting a target of Rs 565 there."

"In the case of Dr Reddy's also we expect another 3-5 percent move on the upside. So these two stocks, we see rollovers are doing better than the other in the pharmaceutical sector. So, we would clearly prefer Dr Reddy's and Sun Pharmaceutical."